“The agreement with Takeda is the first return on investment”

news-single-imgcaption" style="width:240px">Fabien Sebille. Business Development Director of Debipharm (c) Philippe Merle

–

Debiopharm and the pharma group Takeda will collaborate to develop new antibiotics that rebalance the microbiota in order to treat intestinal inflammations. A license agreement for patented compounds in the Debio 1454M program. was signed. It’s a…

– .